Screener
Lexicon Pharmaceuticals LXRX Other, net
Other, net at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.
The source filing: Lexicon Pharmaceuticals’s 10-K, filed March 5, 2026.
- Filed
- Mar 5, 2026, 4:50 PM EST
- Fiscal year
- FY2025
- Accession
- 0001062822-26-000050
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Payments for tax withholding on share-based compensation vesting | (572) | (1,730) | (824) |
| Repayment of debt borrowings | (48,000) | — | — |
| Proceeds from debt borrowings, net of fees | — | — | 49,961 |
| Other debt financing fees | — | (1,307) | — |
| Net cash (used in) provided by financing activities | (48,499) | 238,349 | 187,960 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (3,330) | 44,191 | (23,880) |
| Cash, cash equivalents, and restricted cash at beginning of year | 66,656 | 22,465 | 46,345 |
| Cash, cash equivalents, and restricted cash at end of year | $63,326 | $66,656 | $22,465 |
Item 16. Form 10-K Summary
FAQ
- What is Lexicon Pharmaceuticals's other, net?
- Lexicon Pharmaceuticals (LXRX) reported other, net of $0 in Q4 2025.
- How has Lexicon Pharmaceuticals's other, net changed year-over-year?
- Lexicon Pharmaceuticals's other, net increased by 100.0% year-over-year, from -$1K to $0.
- What does other, net mean?
- Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.
Ask your AI about Lexicon Pharmaceuticals's other, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude